52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
ResTORbio Announces Phase 3 PROTECTOR 1 Trial Of RTB101 In Clinically Symptomatic Respiratory Illness Did Not Meet Primary Endpoint
Restorbio Reports Third Quarter 2019 Financial Results And Corporate Update
Restorbio Posts Q2 Loss Per Share Of $0.51
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.
Biotechnology & Drugs
500 Boylston St Fl 12
President, Chief Executive Officer, Director
John J. McCabe
Vice President - Finance
Vice President - Drug Discovery and Medicinal Chemistry
Chief Scientific Officer
Chief Medical Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Shares of drug developer ResTORbio Inc plunged more than 80% to a record low on Friday after a late-stage trial failure prompted the company to abandon testing its lead drug as a treatment for respiratory illness.
ResTORbio Inc's said on Friday its lead drug missed the main goal in a late-stage testing in patients aged above 65 with respiratory illness.
* RESTORBIO-ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 5.7 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $15.00 PER SHARE Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.